Cytek Biosciences Inc (CTKB)vsEli Lilly and Company (LLY)
CTKB
Cytek Biosciences Inc
$4.31
-1.60%
HEALTHCARE · Cap: $588.89M
LLY
Eli Lilly and Company
$1,155.27
-4.55%
HEALTHCARE · Cap: $1.02T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 35287% more annual revenue ($72.25B vs $204.17M). LLY leads profitability with a 35.0% profit margin vs -36.2%. LLY earns a higher WallStSmart Score of 76/100 (B+).
CTKB
Hold41
out of 100
Grade: D
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+41.3%
Fair Value
$7.43
Current Price
$4.31
$3.12 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 73.5% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of -22.6% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 33.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CTKB
The strongest argument for CTKB centers on EPS Growth, Debt/Equity, Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : CTKB
The primary concerns for CTKB are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.
Key Dynamics to Monitor
CTKB profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
CTKB carries more volatility with a beta of 1.17 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 41/100), backed by strong 35.0% margins and 55.5% revenue growth. CTKB offers better value entry with a 41.3% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytek Biosciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Cytek Biosciences Inc (CTKB) is a pioneering force in multi-parameter flow cytometry, delivering innovative cell analysis solutions that advance research in immunology, cancer diagnostics, and drug development. The company leverages its proprietary technologies to meet the growing demand for precision in cellular analytics, positioning itself as a key player in the biotechnology sector. With a robust product portfolio and a commitment to exceptional customer support, Cytek is well-equipped to drive transformative discoveries, ultimately enhancing healthcare outcomes and addressing critical challenges in the life sciences.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?